Adjuvant trastuzumab in HER2-positive breast cancer.

Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. We randomly...

Full description

Bibliographic Details
Main Authors:	Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, Arlene, Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M., Riva, A., Crown, J., Breast, C.
Format:	Journal Article
Published:	2011
Online Access:	http://hdl.handle.net/20.500.11937/38973

Internet

http://hdl.handle.net/20.500.11937/38973

Adjuvant trastuzumab in HER2-positive breast cancer.

Internet

Similar Items